Clinicians offering early access to Grail’s multi-cancer early detection (MCED) blood test are waiting for full NHS trial readouts after a key endpoint miss. The situation is unfolding ahead of an anticipated FDA regulatory decision, leaving uncertainty about whether the test is ready for wider use. The reporting frames a practical tension: trial limitations are being reviewed by medical groups while discussions continue around whether the evidence base is sufficient to support broader adoption in routine care. For biotech in diagnostics, the episode highlights the fragility of commercialization paths for screening technologies where performance thresholds, clinical utility endpoints, and regulatory expectations must align. Near-term visibility for MCED developers will likely depend on final trial messaging and any regulator guidance on next-step evidence.